

PDR®
46
EDITION
1992

PHYSICIANS'
DESK
REFERENCE®

APOTEX EXHIBIT 1029
Apotex v. Alkermes
IPR2025-00514

PDR®
46
EDITION
1992

PHYSICIANS'
DESK
REFERENCE®

Director of Production:
MARJORIE A. DUFFY

Assistant Director of Production:
CARRIE WILLIAMS

Manager of Production Services:
ELIZABETH H. CARUSO

Format Editor:
MILDRED M. SCHUMACHER

Production Coordinator:
ELIZABETH A. KARST

Art Associate:
JOAN K. AKERLIND

Medical Consultant:
LOUIS V. NAPOLITANO, MD

Product Manager:
JOHN A. MALCZYNSKI

Sales Manager:
CHARLIE J. MEITNER

Account Managers:
CHAD E. ALCORN
MICHAEL S. SARAJIAN
JOANNE C. TERZIDES

Commercial Sales Manager:
ROBIN B. BARTLETT

Direct Marketing Manager:
ROBERT W. CHAPMAN

Manager, Professional Data:
MUKESH MEHTA, R.Ph.

Index Editor:
ADELE L. DOWD

 Copyright ©1992 and published by Medical Economics Data, a division of Medical Economics Company Inc., at Montvale, N.J. 07645. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE®, PDR®, PDR For Ophthalmology®, PDR For Nonprescription Drugs®, PDR Drug Interactions and Side Effects® and PDR Indications Index™ are trademarks of Medical Economics Company Inc., registered in the United States Patent and Trademark Office.

Officers of Medical Economics Data, a division of Medical Economics Company Inc.: President and Chief Executive Officer: Norman R. Snesli; Senior Vice President and Chief Financial Officer: Joseph T. Deithorn; Senior Vice President of Business Development, Stephen J. Sorkenn; Senior Vice President of Operations: Mark L. Weinstein; Vice President, Sales and Marketing: Thomas F. Rice; Vice President of Circulation: Scott I. Rockman; Vice President of Information Services: Edward J. Zecchini.

ISBN 1-56363-003-6

NALTREXONE HYDROCHLORIDE		NIACINAMIDE		Transderm-Nitro Transdermal Therapeutic System (Summit) 432, 2283		NORETHYNODREL	
Trexan Tablets (Du Pont Multi-Source Products) 937		B-C-Bid Capsules (Geriatric) 1052		NITROGLYCERIN INTRAVENOUS		Enovid 5 mg (Searle) 2161	
NANDROLONE DECANOATE		Eldercaps (Mayrand Pharmaceuticals) 1359		Nitro-Bid IV (Marion Merrell Dow) 1338		Enovid 10 mg (Searle) 2161	
Deca-Durabolin (Organon) 1636		Eldertonic (Mayrand Pharmaceuticals) 1359		Nitrostat IV Ampoules & Vials (Parke-Davis) 422, 1744		NORFLOXACIN	
NANDROLONE PHENPROPIONATE		I.L.X. B ₂ Tablets Crystalline (Kenwood) 1163		Nitrostat IV Infusion Kit (Parke-Davis) 1744		Chibroxin Sterile Ophthalmic Solution (Merck Sharp & Dohme) 1431	
Durabolin (Organon) 1636		May-Vita Elixir (Mayrand Pharmaceuticals) 1359		Tridil Ampuls & Vials (Du Pont Multi-Source Products) 939		Noroxin Tablets (Merck Sharp & Dohme) 419, 1519	
NAPHAZOLINE HYDROCHLORIDE		Mega-B (Arco) 607		NIZATIDINE		NORGESTIMATE	
4-Way Fast Acting Nasal Spray (regular & mentholated) & Metered Spray Pump (regular) (Bristol-Myers Products) 751		Natalins Rx (Mead Johnson Laboratories) 418, 1391		Axid Pulvules (Lilly) 416, 1246		Ortho-Cyclen Tablets (Ortho Pharmaceutical) 1658	
Naphcon-A Ophthalmic Solution (Alcon Laboratories) 571		Natalins Tablets (Mead Johnson Laboratories) 418, 1391		NONOXYNOL-9		NORGESTREL	
Privine Hydrochloride 0.05% Nasal Solution (CIBA Pharmaceutical) 878		Prenate 90 Tablets (Bock) 673		Semicid Vaginal Contraceptive Inserts (Whitehall) 435, 2422		Lo/Ovral Tablets (Wyeth-Ayerst) 436, 2471	
Privine Hydrochloride 0.05% Nasal Spray (CIBA Pharmaceutical) 878		Vicon Forte Capsules (Whitby) 434, 2416		Today Vaginal Contraceptive Sponge (Whitehall) 435, 2422		Lo/Ovral-28 Tablets (Wyeth-Ayerst) 436, 2476	
NAPROXEN		NICARDIPINE HYDROCHLORIDE		NOREPINEPHRINE BITARTRATE		Ovral Tablets (Wyeth-Ayerst) 436, 2490	
Naprosyn Suspension (Syntex) 432, 2297		Cardene Capsules (Syntex) 432, 2290		Levophed Bitartrate Injection (Sanofi Winthrop Pharmaceuticals) 2054		Ovral-28 Tablets (Wyeth-Ayerst) 436, 2491	
Naprosyn Tablets (Syntex) 432, 2297		NICLOSAMIDE		NORETHINDRONE		Ovrette Tablets (Wyeth-Ayerst) 2492	
NAPROXEN SODIUM		Niclocide Chewable Tablets (Miles Pharmaceutical) 420, 1607		Breivon 21-Day Tablets (Syntex) 432, 2304		NORTRIPTYLINE HYDROCHLORIDE	
Anaprox and Anaprox DS Tablets (Syntex) 432, 2288		NICOTINAMIDE		Breivon 28-Day Tablets (Syntex) 432, 2304		Pamelor Capsules (Sandoz Pharmaceuticals) 427, 2019	
NEOMYCIN SULFATE		I.L.X. B ₂ Elixir Crystalline (Kenwood) 1163		Jenest-28 Tablets (Organon) 420, 1636		Pamelor Solution (Sandoz Pharmaceuticals) 2019	
Coly-Mycin S Otic w/Neomycin & Hydrocortisone (Parke-Davis) 1708		NICOTINE POLACRILEX		Micronor Tablets (Ortho Pharmaceutical) 421, 1667		NYLIDRIN HYDROCHLORIDE	
Cortisporin Cream (Burroughs Wellcome) 757		Nicorette (Marion Merrell Dow) 417, 1335		Modicon 21 Tablets (Ortho Pharmaceutical) 421, 1667		Arlidin Tablets (Rhône-Poulenc Rorer Pharmaceuticals) 1837	
Cortisporin Ointment (Burroughs Wellcome) 758		NICOTINIC ACID (see also under NIACIN)		Modicon 28 Tablets (Ortho Pharmaceutical) 1667		Nylidrin HCl Tablets (Geneva) 1050	
Cortisporin Ophthalmic Ointment Sterile (Burroughs Wellcome) 758		Niacor Tablets (Upsher-Smith) 2376		N.E.E. 5/35 Tablets (Lexis) 1245		NYSTATIN	
Cortisporin Ophthalmic Suspension Sterile (Burroughs Wellcome) 759		Nicobid (Rhône-Poulenc Rorer Pharmaceuticals) 427, 1846		N.E.E. 1/35 Tablets (Lexis) 1245		Mycolog II Cream and Ointment (Westwood-Squibb) 2407	
Cortisporin Otic Solution Sterile (Burroughs Wellcome) 760		Nicolar Tablets (Rhône-Poulenc Rorer Pharmaceuticals) 1846		N.E.E. 1/50 Tablets (Lexis) 1245		Mycostatin Cream, Ointment, Topical Powder (Westwood-Squibb) 2408	
Cortisporin Otic Suspension Sterile (Burroughs Wellcome) 760		Sio-Niacin Tablets (Upsher-Smith) 433, 2376		N.E.E. 10/11 Tablets (Lexis) 1245		Mycostatin Oral Suspension (Apothecon) 605	
LazerSporin-C Solution (Pedinol) 1770		NIFEDIPINE		Nelova (Warner Chilcott) 2393		Mycostatin Oral Tablets (Apothecon) 605	
NeoDecadron Sterile Ophthalmic Ointment (Merck Sharp & Dohme) 1517		Adalat Capsules (10 mg and 20 mg) (Miles Pharmaceutical) 420, 1587		Norethin 1/35E-21 (Schlapparelli Searle) 428, 2133		Mycostatin Pastilles (Bristol-Myers Oncology) 406, 734	
NeoDecadron Sterile Ophthalmic Solution (Merck Sharp & Dohme) 1518		Nifedipine Capsules (Warner Chilcott) 2393		Norethin 1/35E-28 (Schlapparelli Searle) 428, 2133		Mytrex Cream & Ointment (Savage) 427, 2080	
NeoDecadron Topical Cream (Merck Sharp & Dohme) 1518		Procordia Capsules (Pfizer Labs Division) 423, 1781		Norethin 1/50M-21 (Schlapparelli Searle) 428, 2133		Nystatin Oral Suspension, USP (Warner Chilcott) 2393	
Neomycin Sulfate Tablets (Biocraft) 672		Procordia XL Extended Release Tablets (Pfizer Labs Division) 423, 1783		Norethin 1/50M-28 (Schlapparelli Searle) 428, 2133		Nystatin Oral Suspension (Biocraft) 672	
Neomycin Sulfate Tablets (Roxane) 1983		NIMODIPINE		Norinyl 1 + 35 21-Day Tablets (Syntex) 432, 2304		Nystatin Tablets (Par) 1686	
Neosporin Cream (Burroughs Wellcome) 792		Nimotop Capsules (Miles Pharmaceutical) 420, 1607		Norinyl 1 + 35 28-Day Tablets (Syntex) 432, 2304		Nystatin USP for Extemporaneous Preparation of Oral Suspension (Paddock) 1685	
Neosporin G.U. Irrigant Sterile (Burroughs Wellcome) 793		NITROFURANTOIN		Norinyl 1 + 50 21-Day Tablets (Syntex) 432, 2304		O	
Neosporin Ointment (Burroughs Wellcome) 793		Macrofurantin Capsules (Norwich Eaton) 420, 1624		Norinyl 1 + 50 28-Day Tablets (Syntex) 432, 2304		OCTOCRYLENE	
Maximum Strength Neosporin Ointment (Burroughs Wellcome) 793		NITROFURANTOIN MACROCRYSTALS		Norlutin (Parke-Davis) 422, 1755		Solbar PF Ultra Cream SPF 50 (PABA Free) (Persön & Covey) 1773	
Neosporin Ophthalmic Ointment Sterile (Burroughs Wellcome) 793		Macrofurantin Capsules (Norwich Eaton) 420, 1624		Nor-Q D Tablets (Syntex) 432, 2304		OCTOXYNOL-9	
Neosporin Ophthalmic Solution Sterile (Burroughs Wellcome) 794		NITROFURAZONE		Ortho-Novum 1/35□21 Tablets (Ortho Pharmaceutical) 421, 1667		Messingill Fragrance-Free Soft Cloth Towlette (SmithKline Beecham Consumer Brands) 2192	
Neo-Synalar Cream (Syntex) 2296		Furacin Soluble Dressing (Roberts) 424, 1854		Ortho-Novum 1/35□28 Tablets (Ortho Pharmaceutical) 1667		Messingill Liquid Concentrate (SmithKline Beecham Consumer Brands) 2191	
PediOtic Suspension Sterile (Burroughs Wellcome) 797		Furacin Topical Cream (Roberts) 424, 1854		Ortho-Novum 1/50□21 Tablets (Ortho Pharmaceutical) 421, 1667		OCTREOTIDE ACETATE	
NEOSTIGMINE BROMIDE		Furacin Topical Solution 0.2% (Roberts) 1855		Ortho-Novum 7/7/7 □21 Tablets (Ortho Pharmaceutical) 421, 1667		Sandostatin Injection (Sandoz Pharmaceuticals) 427, 2029	
Prostigmin Tablets (ICN Pharmaceuticals) 1121		NITROGLYCERIN		Ortho-Novum 7/7/7 □28 Tablets (Ortho Pharmaceutical) 1667		OCTYL DIMETHYL PABA	
NEOSTIGMINE METHYLSULFATE		Deponit NTG Transdermal Delivery System (Schwarz Pharma) 429, 2143		Ortho-Novum 10/11□21 Tablets (Ortho Pharmaceutical) 421, 1667		Herpecin-L Cold Sore Lip Balm (Campbell) 833	
Neostigmine Methylsulfate Injection USP (Apothecon) 601		Minitran Transdermal Delivery System (3M Pharmaceuticals) 416, 1312		Ortho-Novum 10/11□28 Tablets (Ortho Pharmaceutical) 1667		Solbar Plus 15 Cream (Persön & Covey) 1772	
Neostigmine Methylsulfate Injection (Astra) 629		Nitro-Bid Ointment (Marion Merrell Dow) 1339		Ovcon 35 (Mead Johnson Laboratories) 418, 1391		OCTYL METHOXYCINNAMATE	
Neostigmine Methylsulfate Injection (Elkins-Sinn) 959		Nitro-Bid 2.5 Plateau Caps (Marion Merrell Dow) 417, 1338		Ovcon 50 (Mead Johnson Laboratories) 418, 1391		DML Facial Moisturizer with Sunscreen (Persön & Covey) 1772	
Neostigmine Methylsulfate Injection (Geneva Marsam) 1050		Nitro-Bid 6.5 Plateau Caps (Marion Merrell Dow) 417, 1338		Tri-Norinyl 21-Day Tablets (Syntex) 432, 2304		Eucerin Daily Facial Lotion (Beiersdorf) 662	
Prostigmin Injectable (ICN Pharmaceuticals) 1120		Nitro-Bid 9 Plateau Caps (Marion Merrell Dow) 417, 1338		Tri-Norinyl 28-Day Tablets (Syntex) 432, 2304		Purpose Dual Treatment Moisturizer with Sunscreen (SPF 12) (Ortho Pharmaceutical (Dermatological Div.)) 1680	
NETILMICIN SULFATE		Nitrogard Tablets (Forest Pharmaceuticals) 1004		NORETHINDRONE ACETATE		Solbar PF 15 Cream (PABA Free) (Persön & Covey) 1772	
Netromycin Injection 100 mg/ml (Schering) 2104		Nitroglycerin S.R. Capsules (Geneva) 1050		Aygestin Tablets (Wyeth-Ayerst) 435, 2437		Solbar PF 15 Liquid (PABA Free) (Persön & Covey) 1772	
NIACIN		Nitroglycerin S.R. Capsules (Lederle) 1192		Loestrin □ 1/20 (Parke-Davis) 422, 1728		Solbar PF Ultra Cream SPF 50 (PABA Free) (Persön & Covey) 1773	
Nia-Bid Capsules (Geriatric) 1053		Nitroglyn Extended Release Capsules (Kenwood) 1163		Loestrin □ 1/30 (Parke-Davis) 422, 1728		OCTYL SALICYLATE	
Niacels Capsules (Hauck) 1080		Nitrolingual Spray (Rhône-Poulenc Rorer Pharmaceuticals) 424, 1846		Loestrin □ 1/20 (Parke-Davis) 422, 1728		Eucerin Daily Facial Lotion (Beiersdorf) 662	
Niacor Tablets (Upsher-Smith) 2376		Nitrong 2.6 mg. Tablets (Rhône-Poulenc Rorer Pharmaceuticals) 1837		Loestrin □ 1/30 (Parke-Davis) 422, 1728		OFLOXACIN	
Nicobid (Rhône-Poulenc Rorer Pharmaceuticals) 427, 1846		Nitrong 6.5 mg. Tablets (Rhône-Poulenc Rorer Pharmaceuticals) 1837		Norlestrin □ 1/50 (Parke-Davis) 422, 1746		Floxin Tablets (Ortho Pharmaceutical) 421, 1652	
Nicolar Tablets (Rhône-Poulenc Rorer Pharmaceuticals) 1846		Nitrostat Tablets (Parke-Davis) 422, 1743		Norlestrin □ 2.5/50 (Parke-Davis) 422, 1746		OLSALAZINE SODIUM	
Sio-Niacin Tablets (Upsher-Smith) 433, 2376		Transdermal-NTG (Warner Chilcott) 2393		Norlestrin □ 2.5/50 (Parke-Davis) 422, 1746		Dipentum Capsules (Kabi Pharmacia) 1160	

ing high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.

Occasionally, patients whose responses are not optimal with SYMMETREL at 200 mg daily may benefit from an increase up to 400 mg daily in divided doses. However, such patients should be supervised closely by their physicians.

Patients initially deriving benefit from SYMMETREL not uncommonly experience a fall-off of effectiveness after a few months. Benefit may be regained by increasing the dose to 300 mg daily. Alternatively, temporary discontinuation of SYMMETREL for several weeks, followed by reinitiation of the drug, may result in regaining benefit in some patients. A decision to use other antiparkinson drugs may be necessary.

Dosage for Concomitant Therapy

Some patients who do not respond to anticholinergic antiparkinson drugs may respond to SYMMETREL. When SYMMETREL or anticholinergic antiparkinson drugs are each used with marginal benefit, concomitant use may produce additional benefit.

When SYMMETREL and levodopa are initiated concurrently, the patient can exhibit rapid therapeutic benefits. SYMMETREL should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit.

When SYMMETREL is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of SYMMETREL.

Dosage for Drug-Induced Extrapyramidal Reactions:

Adult: The usual dose of SYMMETREL (amantadine hydrochloride) is 100 mg twice a day. Occasionally, patients whose responses are not optimal with SYMMETREL at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses.

Dosage for Prophylaxis of Influenza A Virus Illness and Treatment of Uncomplicated Influenza A Virus Illness:

Normal Renal Function:

Adult: The adult daily dosage of SYMMETREL (amantadine hydrochloride) is 200 mg: two 100 mg capsules (or four teaspoonfuls of syrup) as a single daily dose, or the daily dosage may be split into one capsule of 100 mg (or two teaspoonfuls of syrup) twice a day. If central nervous system effects develop on once-a-day dosage, a split dosage schedule may reduce such complaints. In persons 65 years of age or older, the daily dosage of SYMMETREL is 100 mg.

Children: 1 yr.-9 yrs. of age: The total daily dose should be calculated on the basis of 2 to 4 mg/lb/day (4.4 to 8.8 mg/kg/day), but not to exceed 150 mg per day.

9 yrs.-12 yrs. of age: The total daily dose is 200 mg given as one capsule of 100 mg (or two teaspoonfuls of syrup) twice a day.

Impaired Renal Function: Depending upon creatinine clearance, the following dosage adjustments are recommended:

CREATININE CLEARANCE (ml/min/1.73m ²)	SYMMETREL DOSAGE
30-50	200 mg 1st day and 100 mg each day thereafter
15-29	200 mg 1st day followed by 100 mg on alternate days
<15	200 mg every 7 days

The recommended dosage for patients on hemodialysis is 200 mg every 7 days.

Prophylactic dosing should be started in anticipation of an influenza A outbreak and before or after contact with individuals with influenza A virus respiratory tract illness.

SYMMETREL should be continued daily for at least 10 days following a known exposure. If SYMMETREL is used chemoprophylactically in conjunction with inactivated influenza A virus vaccine until protective antibody responses develop, then it should be administered for 2 to 3 weeks after the vaccine has been given. When inactivated influenza A virus vaccine is unavailable or contraindicated, SYMMETREL should be administered for up to 90 days in case of possible repeated and unknown exposures. Treatment of influenza A virus illness should be started as soon as possible, preferably within 24 to 48 hours, after onset of signs and symptoms, and should be continued for 24 to 48 hours after the disappearance of signs and symptoms.

HOW SUPPLIED

SYMMETREL (amantadine hydrochloride) is available as capsules (each red, soft gelatin capsule contains 100 mg amantadine hydrochloride) in:

Bottles of 100 NDC 0056-0105-70

Bottles of 500 NDC 0056-0105-85

Hospital Unit-Dose Blister Package of 100 NDC 0056-0105-75

As a syrup (each 5 mL (1 teaspoonful) contains 50 mg amantadine hydrochloride) in:

16 oz. (480 mL) bottles NDC 0056-0205-16.

Store at controlled room temperature (59°-86°F, 15°-30°C).

CAPSULES MANUFACTURED BY

R.P. Scherer—North America

St. Petersburg, Florida 33702

FOR

Du Pont Pharmaceuticals

Wilmington, Delaware 19880

SYMMETREL® is a Registered Trademark of The Du Pont Merck Pharmaceutical Co.

6043-21/Rev. June 1988

TREXAN™

[treks'an]

(naltrexone hydrochloride)

DESCRIPTION

TREXAN (naltrexone hydrochloride), an opioid antagonist, is a synthetic congener of oxymorphone, and is technically, therefore, a thebaine derivative. However, it has no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethyl group. TREXAN (naltrexone hydrochloride) is also related to the potent opioid antagonist, naloxone, or n-allylnoroxymorphone (NARCAN®). TREXAN (naltrexone hydrochloride) is a white, crystalline compound. The hydrochloride salt is soluble in water to the extent of about 100 mg/cc. TREXAN is available in scored tablets containing 50 mg of naltrexone hydrochloride.

TREXAN Tablets also contain: alginate acid, FD&C Yellow 6, microcrystalline cellulose, stearic acid, and sugar.

CLINICAL PHARMACOLOGY

Pharmacodynamic actions: TREXAN (naltrexone hydrochloride) is a pure opioid antagonist. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. [In this context, the term opioid is used to describe 1) classic morphine-like agonists and 2) analgesics possessing agonist and antagonist activity (e.g., butorphanol, nalbuphine and pentazocine).] When co-administered with morphine, on a chronic basis, TREXAN blocks the physical dependence to morphine and presumably other opioids.

TREXAN has few, if any, intrinsic actions besides its opioid blocking properties. However, it does produce some pupillary constriction, by an unknown mechanism.

The administration of TREXAN is not associated with the development of tolerance or dependence.

In subjects physically dependent on opioids, TREXAN will precipitate withdrawal symptomatology.

Clinical studies indicate that 50 mg of TREXAN will block the pharmacologic effects of 25 mg of intravenously administered heroin for periods as long as 24 hours. Other data suggest that doubling the dose of TREXAN provides blockade for 48 hours, and tripling the dose of TREXAN provides blockade for about 72 hours.

While the mechanism of action is not fully understood, the preponderance of evidence suggests that TREXAN blocks the effects of opioids by competitive binding (i.e., analogous to competitive inhibition of enzymes) at opioid receptors. This makes the blockade produced potentially surmountable.

Bioavailability/Pharmacokinetics: Following oral administration, TREXAN (naltrexone hydrochloride) is subject to extensive "first pass" hepatic metabolism (its major route of elimination) with approximately 95% of the absorbed drug being converted to several metabolites. The major metabolite, 6-β-naltrexol, like TREXAN, is believed to be a pure antagonist and may contribute to the pharmacological blockade of opioid receptors. A minor metabolite is 2-hydroxy-3-methoxy-6-β-naltrexol. TREXAN and its metabolites are also conjugated to form additional metabolic products. TREXAN and its metabolites are excreted primarily by the kidney, with fecal excretion being a minor elimination pathway. The urinary excretion of unchanged TREXAN accounts for less than 1% of an oral dose; urinary excretion of unchanged and conjugated 6-β-naltrexol accounts for approximately 38% of an oral dose. The pharmacokinetic profile of TREXAN suggests that TREXAN and its metabolites undergo enterohepatic recycling.

Following the administration of 50 mg TREXAN tablets to 24 healthy adult male volunteers, the C_{max} for TREXAN and its major metabolite, 6-β-naltrexol were 8.6 ng/mL and 99.3 ng/mL, respectively. The maximum concentration (C_{max}), area under the curve (AUC), and amount excreted in the urine for both TREXAN and 6-β-naltrexol increased proportionally as the amount of TREXAN administered increased from 50 mg to 200 mg. The time to maximum concentration (T_{max}) is one hour for both TREXAN and 6-β-naltrexol. The mean elimination half-life (T_{1/2}) values for TREXAN and 6-β-naltrexol are 3.9 hours and 12.9 hours, respectively. The mean elimination half-life (T_{1/2}) and time to maximum concentration (T_{max}) for TREXAN and 6-β-naltrexol are independent of dose. TREXAN does not accumulate during chronic dosing. As predicted by its longer half-life, plasma

levels of 6-β-naltrexol increase by 40% during chronic TREXAN dosing.

The total body clearance of TREXAN is 1.5 L/min, which approximates liver blood flow, and suggests TREXAN is a highly extracted compound. A renal clearance of 127 mL/min for TREXAN suggests it is solely cleared by glomerular filtration. A renal clearance of 283 mL/min for 6-β-naltrexol suggests an additional renal tubular secretory mechanism. The volume of distribution for TREXAN following intravenous administration is estimated to be 1350 liters. In vitro tests with human plasma show TREXAN to be 21% bound to plasma protein over the therapeutic dose range.

In a relative bioavailability study in 24 healthy adult male volunteers, TREXAN tablets were found to be bioequivalent to TREXAN syrup; no differences were observed for C_{max}, AUC, and urinary excretion. As expected, the time to maximum concentration (T_{max}) occurred slightly earlier for the syrup (0.6 hours) than for the tablet (1.0 hr).

INDICATIONS AND USAGE

TREXAN (naltrexone hydrochloride) is indicated to provide blockade of the pharmacologic effects of exogenously administered opioids as an adjunct to the maintenance of the opioid free-state in detoxified formerly opioid-dependent individuals.

There are no data that demonstrate an unequivocally beneficial effect of TREXAN on rates of recidivism among detoxified, formerly opioid-dependent individuals.

CONTRAINDICATIONS

TREXAN is contraindicated in:

- 1) Patients receiving opioid analgesics.
- 2) Opioid dependent patients.
- 3) Patients in acute opioid withdrawal (see WARNINGS).
- 4) Any individual who has failed to pass the NARCAN challenge (see DOSAGE AND ADMINISTRATION section).
- 5) Any individual who has a positive urine screen for opioids.
- 6) Any individual with a history of sensitivity to TREXAN (naltrexone hydrochloride). It is not known if there is any cross-sensitivity with naloxone or other phenanthrene containing opioids.
- 7) Any individual with acute hepatitis or liver failure.

WARNINGS

Hepatotoxicity:

TREXAN has the capacity to cause dose related hepatocellular injury.

Prior to making a decision to initiate treatment with TREXAN, the physician should establish whether the patient has subclinical liver injury or disease. (See PRECAUTIONS; Laboratory Tests.) TREXAN is contraindicated in acute hepatitis or liver failure, but its use even in patients with evidence of less severe liver disease or a history of recent liver disease must be carefully considered in light of its hepatotoxic potential.

The evidence that identified TREXAN as a hepatotoxin was not obtained in studies involving its use at the doses recommended for opiate blockade, where the changes in serum levels of liver enzymes seen were similar to those present at baseline in the study population. However, the margin of separation between the apparently safe and the hepatotoxic doses appears to be only five-fold or less.

Evidence of TREXAN's hepatotoxic potential is derived primarily from a placebo controlled study in which TREXAN was administered to obese subjects at a dose approximately five-fold that recommended for the blockade of opiate receptors (300 mg per day). In the study, 5 of 26 TREXAN recipients developed elevations of serum transaminases (i.e., peak SGPT values ranging from a low of 121 to a high of 532; or 3 to 19 times their baseline values) after three to eight weeks of treatment. Although the patients involved were generally clinically asymptomatic and the transaminase levels of all patients on whom follow-up was obtained returned to (or toward) baseline values in a matter of weeks, the lack of any transaminase elevations of similar magnitude in any of the 24 placebo patients in the same study is persuasive evidence that TREXAN is a direct (i.e., not an idiosyncratic) hepatotoxin. This conclusion is also supported by evidence from other placebo controlled studies in which exposure to TREXAN at doses from one to two-fold the amount recommended for opiate blockade consistently produced more numerous and more significant elevations of serum transaminases than did placebo, and reports of transaminase elevations in 3 of 9 patients with Alzheimer's Disease who received TREXAN (up to 300 mg/day) for 5 to 8 weeks in an open clinical trial.

Unintended Precipitation of Abstinence: To prevent occurrence of an acute abstinence syndrome, or exacerbation of a pre-existing sub-clinical abstinence syndrome, patients should remain opioid-free for a minimum of 7-10 days before starting TREXAN. Since the absence of an opioid drug in the

Continued on next page

Du Pont Multi-Source—Cont.

urine is often not sufficient proof that a patient is opioid-free, a NARCAN challenge should be employed to exclude the possibility of precipitating a withdrawal reaction following administration of TREXAN. The NARCAN challenge test is described in the DOSAGE AND ADMINISTRATION section. While TREXAN is a potent antagonist with a prolonged pharmacologic effect (24 to 72 hours), the blockade produced by TREXAN is surmountable. This is useful in patients who may require analgesia, but poses a potential risk to individuals who attempt, on their own, to overcome the blockade by administering large amounts of exogenous opioids. Indeed, any attempt by a patient to overcome the antagonism by taking opioids is very dangerous and may lead to a fatal overdose. Injury may arise because the plasma concentration of exogenous opioids attained immediately following their acute administration may be sufficient to overcome the competitive receptor blockade. As a consequence, the patient may be in immediate danger of suffering life endangering opioid intoxication (e.g., respiratory arrest, circulatory collapse). Also, lesser amounts of exogenous opioids may prove dangerous if they are taken in a manner (i.e. relatively long after the last dose of naltrexone) and in an amount so that they persist in the body longer than effective concentrations of naltrexone and its metabolites. Patients should be told of the serious consequences of surmounting the opiate blockade. See Information for Patients section.

PRECAUTIONS

General:

Actions Suggested When Reversal of TREXAN Blockade is Required: In an emergency situation requiring analgesia which can only be achieved with opioids, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged. No methods to reverse overdose have been established by controlled clinical trials; therefore in such circumstances, a rapidly acting analgesic which minimizes respiratory depression is preferred. The amount of analgesic administered should be titrated to the needs of the patient. Additionally, non-receptor mediated actions may occur (e.g., facial swelling, itching, generalized erythema presumably due to histamine release).

Irrespective of the drug chosen to reverse TREXAN (naltrexone hydrochloride) blockade, the patient should be monitored closely by appropriately trained personnel in a hospital setting.

Actions Suggested When Withdrawal is Accidentally Precipitated With TREXAN: Severe opioid withdrawal syndromes precipitated by the accidental ingestion of TREXAN have been reported in opioid-dependent individuals. Symptoms of withdrawal have usually appeared within five minutes of ingestion of TREXAN and have lasted for up to 48 hours. Mental status changes including confusion, somnolence and visual hallucinations have occurred. Significant fluid losses from vomiting and diarrhea have required intravenous fluid administration. In all cases patients were closely monitored and therapy tailored to meet individual requirements.

Interference With the Action of Narcotic Containing Drug Product: Patients taking TREXAN may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics. Where a non-opioid containing alternative is available, it should be used.

Information for Patients: It is suggested that the prescribing physician relate the following information to patients being treated with TREXAN:

You have been prescribed TREXAN (naltrexone hydrochloride) as part of the comprehensive treatment for your drug dependence. You should carry identification to alert medical personnel to the fact that you are taking TREXAN. A TREXAN medication card may be obtained from your physician and can be used for this purpose. Carrying the identification card should help to ensure that you can obtain adequate treatment in an emergency. If you require medical treatment be sure to tell the treating physician that you are receiving TREXAN therapy.

You should take TREXAN as directed by your physician. If you attempt to self-administer heroin or any other opiate drug, in small doses, you will not perceive any effect. Most important, however, if you attempt to self-administer large doses of heroin or any other narcotic, you may die or sustain serious injury, including coma.

Laboratory tests: Tests designed to detect hepatic injury should be obtained prior to initiation of TREXAN therapy and periodically thereafter. (See WARNINGS section on Hepatotoxicity.)

Periodic testing of all patients after initiation of treatment is critical if the occurrence of TREXAN induced liver damage is to be detected at the earliest possible time. Evaluations, using appropriate batteries of tests to detect liver injury are recommended on a monthly basis during the first six months

of use; thereafter, clinical judgment about the frequency of monitoring must be relied upon.

Laboratory tests which may be used for the separation and detection of morphine, methadone or quinine in the urine and with which TREXAN does not interfere include thin-layer, gas-liquid, and high pressure liquid chromatographic methods.

CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY:

Carcinogenesis: In a two-year carcinogenicity study in rats, there were small increases in the numbers of mesotheliomas in males, and tumors of vascular origin in both sexes. The number of tumors were within the range seen in historical control groups, except for the vascular tumors in females, where the 4% incidence exceeded the historical maximum of 2%.

Mutagenesis: A total of twenty-two distinct tests were performed using bacterial, mammalian, and tissue culture systems. All tests were negative except for weakly positive findings in the *Drosophila* recessive lethal assay and non-specific DNA repair tests with *E. coli*. The significance of these findings is undetermined.

Impairment of Fertility: TREXAN (100 mg/kg, approximately 140 times the human therapeutic dose) caused a significant increase in pseudopregnancy in the rat. A decrease in the pregnancy rate of mated female rats also occurred. The relevance of these observations to human fertility is not known.

Pregnancy: Category C. TREXAN has been shown to have an embryocidal effect in the rat and rabbit when given in doses approximately 140 times the human therapeutic dose. This effect was demonstrated in rats dosed with TREXAN (100 mg/kg) prior to and throughout gestation, and rabbits treated with 60 mg/kg of TREXAN during the period of organogenesis.

There are no adequate and well-controlled studies in pregnant women. TREXAN should be used in pregnancy only when the potential benefit justifies the potential risk to the fetus.

LABOR AND DELIVERY

Whether or not TREXAN affects the duration of labor and delivery is unknown.

NURSING MOTHERS

Whether or not TREXAN is excreted in human milk is unknown. Because many drugs are excreted in human milk, caution should be exercised when TREXAN is administered to a nursing mother.

PEDIATRIC USE

The safe use of TREXAN in subjects younger than 18 years old has not been established.

ADVERSE REACTIONS

While extensive clinical studies evaluating the use of TREXAN in detoxified, formerly opioid dependent individuals failed to identify any single, serious untoward risk of TREXAN use, placebo controlled studies employing up to five-fold higher doses of TREXAN (up to 300 mg per day) than that recommended for use in opiate receptor blockade have shown that TREXAN causes hepatocellular injury in a substantial proportion of patients exposed at this higher dose. (See WARNINGS and PRECAUTIONS: Laboratory Tests.)

Aside from this finding, however, available evidence does not incriminate TREXAN, used at any dose, as a cause of any other serious untoward event for the patient who is "opiate free." It is critical to recognize that TREXAN can precipitate or exacerbate abstinence signs and symptoms in any individual who is not completely free of exogenous opioids.

TREXAN used at the doses recommended to produce opiate receptor blockade does not appear to be the cause of any of the numerous adverse events and abnormal laboratory findings, including liver function abnormalities, that were observed in the course of the clinical trials that enrolled individuals with a history of both alcohol and substance abuse. In the one placebo controlled trial intended to assess the effects of opiate receptor blockade on drug abuse recidivism, observed untoward events and laboratory abnormalities occurred with nearly equal frequency among placebo and TREXAN recipients. In all open studies, the untoward events observed (e.g., lymphocytosis, transaminase elevations, GI disturbances) were findings that would be anticipated in any similar population not treated with naltrexone. Supporting this judgment, many of the abnormalities detected during the course of the clinical trials were present at baseline, and in some instances, baseline abnormalities, including transaminase elevations, improved or returned to normal during the course of treatment with naltrexone. In summary, among opioid free individuals, TREXAN administration at the recommended dose has not been associated with a predictable profile of serious adverse or untoward events. However, as mentioned above, among individuals using opioids, TREXAN may cause serious reactions (see CONTRAINDICATIONS, WARNINGS, DOSAGE AND ADMINISTRATION).

Events other than hepatocellular injury reported during clinical testing:

The following adverse reactions have been reported both at baseline and during the TREXAN medication period at an incidence rate of more than 10%:

Difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea and/or vomiting, low energy, joint and muscle pain, and headache.

The incidence was less than 10% for:

Loss of appetite, diarrhea, constipation, increased thirst, increased energy, feeling down, irritability, dizziness, skin rash, delayed ejaculation, decreased potency, and chills.

The following events occurred in less than 1% of subjects:

Respiratory: nasal congestion, itching, rhinorrhea, sneezing, sore throat, excess mucus or phlegm, sinus trouble, heavy breathing, hoarseness, cough, shortness of breath.

Cardiovascular: nose bleeds, phlebitis, edema, increased blood pressure, non-specific ECG changes, palpitations, tachycardia.

Gastrointestinal: excessive gas, hemorrhoids, diarrhea, ulcer.

Musculoskeletal: painful shoulders, legs or knees; tremors, twitching.

Genitourinary: increased frequency of or discomfort during urination; increased or decreased sexual interest.

Dermatologic: oily skin, pruritus, acne, athlete's foot, cold sores, alopecia.

Psychiatric: depression, paranoia, fatigue, restlessness, confusion, disorientation, hallucinations, nightmares, bad dreams.

Special senses: eyes-blurred, burning, light sensitive, swollen, aching, strained; ears "clogged", aching, tinnitus.

General: increased appetite, weight loss, weight gain, yawning, somnolence, fever, dry mouth, head "pounding", inguinal pain, swollen glands, "side" pains, cold feet, "hot spells." Lethargy and somnolence have been reported following dosing of TREXAN (naltrexone hydrochloride) and thioridazine.

Laboratory tests: With the exception of liver test abnormalities in investigator studies (see WARNINGS, PRECAUTIONS, etc.), results of laboratory tests, like adverse reaction reports, have not shown consistent patterns of abnormalities that can be attributed to treatment with TREXAN.

In the trials evaluating TREXAN for the blockade of opiate receptors, abnormal liver function tests and lymphocytosis were the two most common categories of abnormalities reported. As noted earlier, these abnormalities are common among populations of parenteral opiate users and alcoholics. As is the case with the untoward events described above, a large proportion of patients had abnormal laboratory tests at baseline, further supporting the conclusion that the abnormalities observed are not attributable to TREXAN.

Idiopathic thrombocytopenic purpura was reported in one patient who may have been sensitized to TREXAN in a previous course of treatment with TREXAN. The condition cleared without sequelae after discontinuation of TREXAN and corticosteroid treatment.

DRUG ABUSE AND DEPENDENCE

TREXAN is a pure opioid antagonist. It does not lead to physical or psychological dependence. Tolerance to the opioid antagonist effect is not known to occur.

OVERDOSAGE

There is no clinical experience with TREXAN overdosage in humans. In one study, subjects who received 800 mg daily TREXAN for up to one week showed no evidence of toxicity. In the mouse, rat and guinea pig, the oral LD₅₀s were 1,100 ± 96 mg/kg; 1,450 ± 265 mg/kg; and 1,490 ± 102 mg/kg, respectively.

In acute toxicity studies in the mouse, rat, and dog, cause of death was due to clonic-tonic convulsions and/or respiratory failure.

TREATMENT OF OVERDOSAGE

Consideration should be given to contacting a poison control center for the most up-to-date information.

In view of the lack of actual experience in the treatment of TREXAN overdose, patients should be treated symptomatically in a closely supervised environment.

DOSAGE AND ADMINISTRATION

Induction of TREXAN Therapy: DO NOT ATTEMPT TREATMENT UNTIL NARCAN CHALLENGE IS NEGATIVE (see below). Initiate treatment with TREXAN using the following guidelines:

1. Treatment should not be attempted until the patient has remained opioid-free for 7-10 days. Self-reporting of abstinence from opioids should be verified by analysis of the patient's urine for absence of opioids. The patient should not be manifesting withdrawal signs or reporting withdrawal symptoms.
2. A NARCAN challenge test (see below) should be administered to the patient. If signs of opioid withdrawal are still observed following NARCAN challenge, treatment with TREXAN should not be attempted. The NARCAN challenge can be repeated in 24 hours.

3. Treatment should be initiated carefully, slowly increasing the dose of TREXAN administered. This can be accomplished by administration of 25 mg of TREXAN initially. The patient should be observed for 1 hour. If no withdrawal signs occur, the patient may be given the rest of the daily dose.

NARCAN Challenge Test: The NARCAN challenge test should *not* be performed in a patient showing clinical signs or symptoms of opioid withdrawal, or in a patient whose urine contains opioids.

The NARCAN challenge test may be administered by either the intravenous or subcutaneous routes.

Intravenous challenge: Following appropriate screening of the patient, 0.8 mg of NARCAN should be drawn into a sterile syringe. If the intravenous route of administration is selected, 0.2 mg of NARCAN should be injected, and while the needle is still in the patient's vein, the patient should be observed for 30 seconds for evidence of withdrawal signs or symptoms. If there is no evidence of withdrawal, the remaining 0.6 mg of NARCAN should be injected, and the patient observed for an additional period of 20 minutes for signs and symptoms of withdrawal.

Subcutaneous challenge: If the subcutaneous route is selected, 0.8 mg should be administered subcutaneously, and the patient observed for signs and symptoms of withdrawal for 45 minutes.

Conditions and technique for observation of patient: During the appropriate period of observation, the patient's vital signs should be monitored and the patient should be monitored for signs of withdrawal. It is also important to question the patient carefully. The signs and symptoms of opioid withdrawal include, but are not limited to, the following:

WITHDRAWAL SIGNS: stuffiness or running nose, tearing, yawning, sweating, tremor, vomiting or piloerection.

WITHDRAWAL SYMPTOMS: feeling of temperature change, joint or bone and muscle pain, abdominal cramps, skin crawling, etc.

Interpretation of the Challenge: Warning: the elicitation of the enumerated signs or symptoms indicates a potential risk for the subject, and TREXAN should not be administered. If no signs or symptoms of withdrawal are observed, elicited, or reported, TREXAN MAY BE ADMINISTERED. If there is any doubt in the observer's mind that the patient is not in an opioid-free state, or is in continuing withdrawal, NARCAN should be readministered as follows:

Confirmatory rechallenge (if necessary): 1.6 mg of NARCAN should be injected intravenously and the patient again observed for signs and symptoms of withdrawal. If none are present, TREXAN may be administered. If signs and symptoms of withdrawal are present, administration of TREXAN should be delayed until repeated NARCAN challenge indicates the patient is no longer at risk.

Maintenance Treatment: Once the patient has been started on TREXAN, 50 mg every 24 hours will produce adequate clinical blockade of the actions of parenterally administered opioids (i.e., this dose will block the effects of a 25 mg intravenous heroin challenge). A flexible approach to a dosing regimen may be employed. Thus, patients may receive 50 mg of TREXAN every weekday with a 100 mg dose on Saturday or patients may receive 100 mg every other day, or 150 mg every third day. While the degree of opioid blockade may be somewhat reduced by using higher doses at longer dosing intervals, improved patient compliance may result from dosing every 48-72 hours.

Several of the clinical studies reported in the literature have employed the following dosing regimen: 100 mg on Monday, 100 mg on Wednesday, and 150 mg on Friday. This dosing schedule appeared to be acceptable to many TREXAN patients successfully maintaining their opioid free state.

HOW SUPPLIED

TREXAN (naltrexone hydrochloride) tablets are available in 50 mg round tablets, scored imprinted with DuPont on one side and TREXAN on the other. Bottles of 50 tablets (NDC 0056-0080-50).

Protect from excessive light.

NARCAN® is a Registered Trademark of The Du Pont Merck Pharmaceutical Co.

TREXAN™ is a U.S. Trademark of The Du Pont Merck Pharmaceutical Co.

Du Pont Pharmaceuticals
Wilmington, Delaware 19880

6162-3/Rev. Dec., 1988

TRIDIL®
[tri 'dil]
(nitroglycerin)

ERED TO THE PATIENT. (SEE WARNINGS, AND DOSAGE AND ADMINISTRATION SECTIONS).

CAUTION

SEVERAL PREPARATIONS OF NITROGLYCERIN FOR INJECTION ARE AVAILABLE. THEY DIFFER IN CONCENTRATION AND/OR VOLUME PER VIAL. WHEN SWITCHING FROM ONE PRODUCT TO ANOTHER ATTENTION MUST BE PAID TO THE DILUTION AND DOSAGE AND ADMINISTRATION INSTRUCTIONS.

DESCRIPTION

Nitroglycerin in 1,2,3-propanetriol trinitrate, an organic nitrate whose empiric formula is $C_3H_5N_3O_9$, and whose molecular weight is 227.09. The organic nitrates are vasodilators, active on both arteries and veins.

TRIDIL (nitroglycerin) is a clear, practically colorless additive solution for intravenous infusion after dilution. Each mL of TRIDIL 5 mg contains 0.5 mg Nitroglycerin with 4.5 mg Lactose, USP; 10% Alcohol, USP; and 13.8 mg Monobasic Sodium Phosphate, USP as a buffer in Water for Injection, USP. Each mL of TRIDIL 25 mg, TRIDIL 50 mg, or TRIDIL 100 mg contains 5 mg Nitroglycerin in 30% Alcohol, USP; 30% Propylene Glycol, USP; and Water for Injection, USP. The solution is sterile, non-pyrogenic, and nonexplosive.

CLINICAL PHARMACOLOGY

The principal pharmacological action of TRIDIL (nitroglycerin) is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined.

Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than an minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the anti-anginal efficacy of continuously-delivered nitrates. In the large majority of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome nitrate tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their anti-anginal efficacy been restored.

Pharmacokinetics: The volume of distribution of nitroglycerin is about 3 L/kg, and nitroglycerin is cleared from this volume at extremely rapid rates, with a resulting serum half-life of about 3 minutes. The observed clearance rates (close to 1 L/kg/min) greatly exceed hepatic blood flow; known sites of extrahepatic metabolism include red blood cells and vascular walls.

The first products in the metabolism of nitroglycerin are inorganic nitrate and the 1,2- and 1,3-dinitroglycerols. The dinitrates are less effective vasodilators than nitroglycerin, but they are longer-lived in the serum, and their net contribution to the overall effect of chronic nitroglycerin regimens is not known. The dinitrates are further metabolized to (non-vasoactive) mononitrates and, ultimately, to glycerol and carbon dioxide.

To avoid development of tolerance to nitroglycerin drug-free intervals of 10-12 hours are known to be sufficient; shorter intervals have not been well studied. In one well-controlled clinical trial, subjects receiving nitroglycerin appeared to exhibit a rebound or withdrawal effect, so that their exercise tolerance at the end of the daily drug-free interval was less than that exhibited by the parallel group receiving placebo.

Clinical Trials: Blinded, placebo-controlled trials of intravenous nitroglycerin have not been reported, but multiple investigators have reported open-label studies, and there are scattered reports of studies in which intravenous nitroglycerin was tested in blinded fashion against sodium nitropruside.

In each of these studies, therapeutic doses of intravenous nitroglycerin were found to reduce systolic and diastolic arterial blood pressure. The heart rate was usually increased, presumably as a reflexive response to the fall in blood pressure. Coronary perfusion pressure was usually, but not always, maintained.

Intravenous nitroglycerin reduced central venous pressure (CVP), right atrial pressure (RAP), pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), pulmonary vascular resistance (PVR), and systemic vascular resistance (SVR). When these parameters were elevated, reducing them toward normal usually caused a rise in cardiac output. Conversely intravenous nitroglycerin usually reduced cardiac output when it was given to patients whose CVP, RAP, PAP, PCWP, PVR, and SVR were all normal. Most clinical trials of intravenous nitroglycerin have been brief; they have typically followed hemodynamic parameters

during a single surgical procedure. In one careful study, one of the few that lasted more than a few hours, continuous intravenous nitroglycerin had lost almost all of its hemodynamic effect after 48 hours. In the same study, patients who received nitroglycerin infusions for only 12 hours out of each 24 demonstrated no similar attenuation of effect. These results are consistent with those seen in multiple large, double-blind, placebo-controlled trials of other formulations of nitroglycerin and other nitrates.

INDICATIONS AND USAGE

TRIDIL (nitroglycerin) is indicated for treatment of perioperative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and B-blockers; and for induction of intraoperative hypotension.

CONTRAINDICATIONS

Allergic reactions to organic nitrates are extremely rare, but they do occur. TRIDIL is contraindicated in patients who are allergic to it.

WARNINGS

Nitroglycerin readily migrates into many plastics, including the polyvinyl chloride (PVC) plastics commonly used for intravenous administration sets. Nitroglycerin absorption by PVC tubing is increased when the tubing is long, the flow rates are low, and the nitroglycerin concentration of the solution is high. The delivered fraction of the solution's original nitroglycerin content has been 20-60% in published studies using PVC tubing; the fraction varies with time during a single infusion, and no simple correction factor can be used. PVC tubing has been used in most published studies of intravenous nitroglycerin, but the reported doses have been calculated by simply multiplying the flow rate of the solution by the solution's original concentration of nitroglycerin. *The actual doses delivered have been less, sometimes much less, than those reported.*

Some in-line intravenous filters also absorb nitroglycerin; these filters should be avoided.

Because of the absorption problem, the TRIDILSET® i.v. administration set and TRIDILSET V.I.P.® volumetric infusion pump connector set were developed to minimize the loss of TRIDIL. TRIDILSET or TRIDILSET V.I.P. are recommended for infusions of TRIDIL (see DOSAGE AND ADMINISTRATION).

DOSING INSTRUCTIONS MUST BE FOLLOWED WITH CARE. WHEN TRIDILSET/TRIDILSET V.I.P. IS USED, THE CALCULATED DOSE WILL BE DELIVERED TO THE PATIENT, BECAUSE THE LOSS OF TRIDIL SEEN WITH STANDARD PVC TUBING WILL BE AVOIDED. THE DOSAGES REPORTED IN PUBLISHED STUDIES UTILIZED GENERAL-USE PVC ADMINISTRATION SETS, AND RECOMMENDED DOSES BASED ON THIS EXPERIENCE WILL BE TOO HIGH WHEN TRIDILSET/TRIDILSET V.I.P. IS USED.

PRECAUTIONS

General Severe hypotension and shock may occur with even small doses of TRIDIL (nitroglycerin). This drug should therefore be used with caution in patients who may be volume depleted or who, for whatever reason, are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris.

Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.

As tolerance to other forms of nitroglycerin develops, the effect of sublingual nitroglycerin on exercise tolerance, although still observable, is somewhat blunted.

In industrial workers who have had long-term exposure to unknown (presumably high) doses of organic nitrates, tolerance clearly occurs. Chest pain, acute myocardial infarction, and even sudden death have occurred during temporary withdrawal of nitrates from these workers, demonstrating the existence of true physical dependence.

Some clinical trials in angina patients have provided nitroglycerin for about 12 continuous hours of every 24-hour day. During the nitrate-free intervals in some of these trials, anginal attacks have been more easily provoked than before treatment, and patients have demonstrated hemodynamic rebound and decreased exercise tolerance. The importance of these observations to the routine, clinical use of intravenous nitroglycerin is not known.

Lower concentrations of nitroglycerin increase the potential precision of dosing, but these concentrations increase the total fluid volume that must be delivered to the patient. Total fluid load may be a dominant consideration in patients with compromised function of the heart, liver, and/or kidneys.

Nitroglycerin infusions should be administered only via a pump that can maintain a constant infusion rate. Intracoronary injection of nitroglycerin infusions has not been studied.

Continued on next page

FOR INTRAVENOUS USE ONLY. NOT FOR DIRECT INTRAVENOUS INJECTION. TRIDIL® MUST BE DILUTED IN DEXTROSE (5%) INJECTION, USP OR SODIUM CHLORIDE (0.9%) INJECTION, USP PRIOR TO ITS INFUSION (SEE DOSAGE AND ADMINISTRATION SECTION). THE ADMINISTRATION SET USED FOR INFUSION WILL AFFECT THE AMOUNT OF TRIDIL DELIV-

ISBN: 1-56363-003-6